Biogen (BIIB) PT Lowered to $338 at Credit Suisse
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $218.24 -1.5%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Join SI Premium – FREE
Credit Suisse analyst Evan Seigerman lowered the price target on Biogen (NASDAQ: BIIB) to $338.00 (from $350.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Biogen (BIIB) call put ratio 3.7 calls to 1 put with a focus on September calls
- Giant Biogene Holding Co (2367:HK) PT Raised to HK$46 at Macquarie
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
